본문 바로가기 주메뉴 바로가기

제품소개

제품상세페이지

Proteogenix

[Proteogenix] Human FLT1 recombinant protein

Cat-No. PX-P6096


Proteogenix는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.




제품 설명 


Human FLT1 recombinant protein

  



제품 번호

 

PX-P6096

 



제품 특징


Product nameHuman FLT1 recombinant protein
Uniprot IDP17948
Origin speciesHomo sapiens (Human)
Expression systemEukaryotic expression
Molecular weight37.77 kDa
Protein delivered with Tag?C-Terminal His Tag
Purity estimated>85% by SDS-PAGE
Buffer0.01M PBS, pH 7.4.
Delivery conditionDry Ice
Storage condition4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection)
BrandProteoGenix
Host speciesMammalian cells
ApplicationsELISA,WB
Fragment TypeMet1-Ile328
Aliases /SynonymsFLT1, Vascular endothelial Growth Factor proteins receptor 1, VEGFR1, Vascular permeability factor receptor, FRT, Tyrosine-protein kinase receptor FLT, VEGFR-1, FLT, FLT-1, Tyrosine-protein kinase FRT, Fms-like tyrosine kinase 1, Drug Target
ReferencePX-P6096
NoteFor research use only


Description of Human FLT1 recombinant protein

General information on Human FLT1 recombinant protein

Human FLT1 Recombinant Protein: Structure and Activity

Human Fms-like tyrosine kinase 1 (FLT1) is a type I membrane receptor belonging to the vascular endothelial growth factor receptor (VEGFR) family. It is composed of an extracellular domain, a single transmembrane domain, and an intracellular domain. The extracellular domain of FLT1 binds to VEGF-A, VEGF-C, and VEGF-D, while the intracellular domain has tyrosine kinase activity. FLT1 is involved in the regulation of angiogenesis, vascular permeability, and cell proliferation.

FLT1 as an Antibody-Drug Target

FLT1 is an attractive target for antibody-drug conjugates (ADCs) due to its role in tumor growth and angiogenesis. ADCs are composed of an antibody linked to a cytotoxic drug. The antibody binds to the FLT1 receptor and the drug is internalized, leading to cell death. FLT1-targeted ADCs have been used in clinical trials for various types of cancer, including ovarian, gastric, and colorectal cancers.




QC & Validation Data


Icrucumab Biosimilar - Anti-FLT1, VEGFR-1 mAb binds to Human FLT1 recombinant protein in indirect ELISA Assay

Immobilized Human FLT1 recombinant protein (cat. No.PX-P6096) at 0.5µg/mL (100µL/well) can bind to Icrucumab Biosimilar - Anti-FLT1, VEGFR-1 mAb (cat. No.PX-TA1257) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450




ProteoGenix의 모든 제품들을 만나보세요!

 

Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"